Slide 1: Dimerix presents keynote speech at Bio Connections Australia
Immediate Release DIMERIX PRESENTS KEYNOTE SPEECH AT BIO CONNECTIONS AUSTRALIA MELBOURNE, Australia, 29 July 2024: Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in inflammatory disease, is pleased to advise that CEO and Managing Director, Dr Nina Webster, will
Slide 2: About FSGS Phase 3 Study, Dimerix and DMX 200
About FSGS Phase 3 Study The Phase 3 study, which is titled “Angiotensin II Type 1 Receptor (AT1R) & Chemokine Receptor 2 (CCR2) Targets for Inflammatory Nephrosis”, or ACTION3 for short, is a pivotal (Phase 3), multi-centre, randomised, double-blind, placebo-controlled study of the efficacy and saf
Slide 3: Orphan Drug Designation and references
cases diagnosed in the US alone each year. 4 Because there is no effective treatment, Dimerix has received Orphan Drug Designation for DMX 200 in both the US and Europe for FSGS. Orphan Drug Designation is granted to support the development of products for rare diseases and qualifies Dimerix for var
Slide 4: Positioning for Success: Australian Biotech
wo w Dimerix BIO CONNECTIONS wv ASK:DX®) AUSTRALIA 2024 Positioning for Success: Australian Biotech Y qBio Connections 29 July 2024 i Developing new therapies to treat inflammatory causes of kidney and respiratory disease with unmet clinical needs Authorised for lodgement by the Board of the Company
Slide 5: Forward looking statements
Forward looking statements nis presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks on important factors that may cause the actual results, performance or achievements of Dimerix to be materially different from
Slide 6: Corporate overview
Corporate overview Ticker Symbol ASX: DXB Cash Balance (Jun24)* “A$22.1 million for past 30 trading days? Market Capitalisation? ~A$267 million Share price! “A$O.A8 Total ordinary shares on issue? 550,659,795, Average Daily Liquidity by value “$3.62 million Cash balance includes payment of: Cash bal
Slide 7: Dimerix - in context
IMERIX - IN CONTEXT For personal use only @ Dimerix
Slide 8: Lead drug candidate, FSGS indication, commercial validation
Lead Drug Candidate For personal use only • • FSGS Indication • • • Commercial Validation •
Slide 9: Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis (FSGS) How do you measure kidney function? = _ * Historically, measured using “hard” endpoints for kidney disease < Focal = some . kidney failure) -which may not be reached for decades! ° Segmental = sections y y y wo Gl \ f the kid filteri it * Regulatory agencies
Slide 10: Why are kidneys important? Why is proteinuria important?
Why are kidneys important? Why is proteinuria important? For personal use only
Slide 11: Primary endpoint: eGFR (kidney function) - example
Primary endpoint: eGFR (kidney function) - example Natural aging kidney function slope! * Kidney function can be measured using estimated glomerular filtration rate (eGFR): nly fo) o how many millilitres of blood is filtered by the ai’ kidney per minute per year 2 * eGFR slope naturally declines as
Slide 12: Background Phase 3 Trial Timeline
For personal use only Background Phase 3 Trial Timeline • • •
Slide 13: For personal use only
• • • • • • • For personal use only
Slide 14: Typical recruitment curve - S shape example
Typical recruitment curve — S shape example Subject to seasonal holidays a ~ Usually the largest ce expense in clinical trial je) 3 g s Clinic lentified S o > aa oO re ; c 8 Clinical sites opening process:' Oo 8 YN & “= alfone . Oe First sites opening 5 ion je) LL > Protocol approved Clinical sites
Slide 15: ACTION3 study operation - double recruitment curve
O ACTICINS study operation — double recruitment curve FSGS CLINICAL STUDY N=286 ; Lx ZETIONS can anticipate two @ shape” recruitment curves: Tal During part 1; and = — 2. During parts 2 &3 First stage of opening “72 sites Recruitment slows as existing sites start to exhaust patient numbers © Second
Slide 16: Challenges to success along the way
CHALLENGES TO SUCCESS ALONG THE WAY © Cc [e) Y haa oO ios ro (e) LL @ Dimerix
Slide 17: For personal use only
• • For personal use only • • • • • • • • • • •
Slide 18: Getting our ducks in a row
| use only -Or persona GETTING OUR DUCKS IN A ROW al @ Dimerix
Slide 19: Preparing for partnering: development, regulatory, manufacturing, IP
• Container closure, shelf-life & product presentation For personal use only Global regulatory Commercial manufacturing, • pathways/minutes quality, Cost of Goods & supply chain Product development Competitive landscape, (pre-clinical/ epidemiology & market research clinical data) Many years behind
Slide 20: Dimerix partnering executed to plan
Dimerix partnering executed to plan “mmuneats _ = — Materials Product Information Market Analysis Financial Information Partnering All materials are ready at the start of a partnering exercise — ht Potential partners identified as part of business development plan @ Dimerix
Slide 21: Time to deal
Time to deal The time from first meeting to executing a license agreement takes time - it can take up to 2 years St is all in the planning and experience in doing deals: “E* Structure, tactics & outreach ° Pr —) Process management oO ae . «~* Negotiation and execution =) © Cc [e) Dimerix has a numbe
Slide 22: For personal use only
For personal use only
Slide 23: Global partnering trends - Q1 2024
Global partnering trends — Q1 2024 The total number of deals across the sectors is R&D Partnerships — Global Healthcare and Life Sciences’ declining? ec Deal Value ($B) mam Total Upfront Cash and Equity ($B) ®=Number of Deals oan . 2023 and Ql 2024 $73.0 dealmaking environment oe De. we” oe 300 show
Slide 24: Kidney disease is high interest area for pharma
Kidney disease is high interest area for pharma Prevalence of Kidney Failure, 2001-20232 = Kidney disease is the third-fastest-growing ”, cause of death globally! In the US alone, the number of people with kidney failure increased by >200% from 2001 to 2023? By 2040, it is expected to become the fif
Slide 25: Summary of DMX-200 licensing deals
Summary of DMX-200 licensing deals Dimerix has validated the technology! and proven its ability to licence multiple territories, with more deals anticipated Summary ADVANZ & PHARMA pear) Other Licensing Deals (incl. US & China) For personal use sales Escalating mid-teen-20% EEA, Canada, Switzerland,
Slide 26: Lead drug candidate, FSGS indication, commercial validation
Lead Drug Candidate For personal use only • • FSGS Indication • • • Commercial Validation •
Slide 27: Well positioned to deliver our strategic plan
For personal use only A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases. WELL POSITIONED TO DELIVER OUR STRATEGIC PLAN ESG Statement SCAN ME Dimerix HQ 425 Sm